Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

NCT06372626 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Carcinoma

Interventions

BIOLOGICAL: ZG005
DRUG: Etoposide
DRUG: Cisplatin
DRUG: Placebo

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd